Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Receives...

The designation is based on data from a cohort of patients with HL in the company's ongoing Phase 1b study of relapsed and refractory hematological malignancies .

http://ift.tt/1ngjajE